PPT-Switching the NRTI Backbone to Tenofovir DF-Emtricitabine

Author : reese | Published Date : 2023-08-31

TOTEM Switching the NRTI Backbone to Tenofovir DFEmtricitabine TOTEM Study Design Source Valantin MA et al J Antimicrob Chemother 20106555661 TDFFTC Continue

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Switching the NRTI Backbone to Tenofovir..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine: Transcript

TOTEM Switching the NRTI Backbone to Tenofovir DFEmtricitabine TOTEM Study Design Source Valantin MA et al J Antimicrob Chemother 20106555661 TDFFTC Continue 3 rd. John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. Albany Medical Center Hospital. NY/NJ AIDS Education and Training Center. When to Start. DHHS: Changing Criteria for Initiating ART. CD4+ Count, cells/mm. New Treatments for HIV. C. Ryan Tomlin, . Pharm.D. ., BCPS, AAHIVP. Mercy Health Saint Mary’s. Grand Rapids, Michigan. Outline. Newly Released Antiretroviral Medications. Isentress. HD. ® (. raltegravir. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 3rd Quarter. October-December 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Treatment-naïve Patients . Clinical Instructor, Harvard Medical School. Director of Research, CRI New England. Vice Chair, INSIGHT Scientific Steering Committee. Boston, USA . Calvin Cohen, MD, MSc. Drew Lambert, . PharmD. lambertd@husson.edu. Husson University School of Pharmacy. 1. PollEverywhere. - Text . DREWLAMBERT221 to 22333 to join. You . can respond at . PollEv.com/drewlambert221. I have no conflicts of interest.. of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 2nd Quarter. July-September 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 1. st. Quarter. APRIL-JUNE 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. ACTIVITY CODE . TD342. Antiretroviral Medications: . What . you need to know. Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP. Associate Professor, Department of Pharmacy Practice. Clinical Pharmacist – HIV Medicine. Outline. What is HIV?. Common Labs. Life Cycle and Medication Targets. Building an HIV regimen. HIV Guidelines. When to start treatment. What medications to start. STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. Madeline Droney, PharmD. In it for the Long-Haul. Long-Acting Injectables in HIV Treatment. Conflict of Interest. The presenters report no conflict of interest. Review the treatment recommendations for human immunodeficiency virus (HIV) infection. ADONE Trial. Simplification to Efavirenz-Tenofovir DF-Emtricitabine . ADONE: Study Design. Source: . Airoldi. M, et al. Patient Prefer Adherence. 2010;4:115-25.. Study Design: ADONE Study . Background. FTC. Study 311-1089. Switching from TDF/FTC to TAF/. FTC. Study 311: Design. Source. : Gallant JE, et al. Lancet HIV. 2016;3:e158-65.. Switch to TAF/FTC*. . (n = 333). Continue TDF/FTC. (n = 330). *Patients on a pharmacokinetic booster (ritonavir) received tenofovir alafenamide-emtricitabine 10/200 mg.

Download Document

Here is the link to download the presentation.
"Switching the NRTI Backbone to Tenofovir DF-Emtricitabine"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.